Skip to content

Monoclonal Antibodies

FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region

[11/30/2022] The U.S. Food and Drug Administration today announced bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1., according to data included in the Health Care Provider Fact Sheet.

For more information, please click here.

Scroll To Top expand_less

Sign up for Email Updates

Please provide your details below to reach out to our ASAP team on any questions about Antimicrobial Stewardship.

"*" indicates required fields

Address*
Name*
This field is for validation purposes and should be left unchanged.